Home
overview

With the ever-expanding therapeutic market, research and development is fundamental for improving current treatments and the design of protein based drugs of the future. With the variety of protein expression systems rapidly evolving, there is more pressure to harvest larger, purer quantities of product. Furthermore, a vast number of biomarker discovery studies have recently been embarked upon, requiring new, more efficient methods to identify and analyse proteins involved in disease populations with the aim to discover novel diagnostic tools and treatments.

SMi’s 4th annual Global Protein Summit is designed to meet the needs of the industry. It is an excellent opportunity to hear about the latest developments from leaders in the field, bringing together experts in protein expression, purification, identification and functional analysis. 

This event will bring together Vice Presidents, Directors, Heads and leading researchers from the pharmaceutical industry to share their knowledge and discuss the critical issues surrounding the development of innovative protein drug compounds. It’s a must attend event for all those involved in protein research and development.



Critical challenges that will be addressed:
  • GENE TO PROTEIN: Analyse the challenges with protein engineering and expression
  • PROTEOMICS: Gain an insight into the role of biomarkers and the recent advances in this area
  • PROTEIN PRODUCTION: Understand multi-parallel and high throughput systems
  • EXPRESSION TECHNOLOGIES: Learn about novel technologies that are being developed for a variety of compounds
  • PURIFICATION & ANALYSIS: Discuss how to effectively analyse, characterise and purify protein material



Exclusive presentations from industry experts including:

  • Paul Ramage, Senior Research Investigator 1, CPC/Protease Platform, Novartis Pharma AG
  • Mark McAlister, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca
  • Florian Wurm, Professor of Biotechnology, Ecole Polytechnique Federale de Lausanne
  • Joseph Siemiatkoski, Senior Scientist, Analytical Development, Biogen Idec
  • Indresh Srivastava, Head of Protein Biology, Protein Biology, Novartis
  • Bernardo Perez-Ramirez, Scientific Director, Bioformulations Development, Genzyme Corporation
  • Mark Abbott, Principal Scientist, Respiratory and Inflammation, AstraZeneca
  • Renos Savva, Senior Research Fellow, School of Crystallography, Birkbeck College, University of London
  • Kent Bondensgaard, Research Scientist, Novo Nordisk
  • Ingrid Marchal-Gerez, Business Development Manager, Proteus
  • Ian Hunt, Group leader, Protein Structure Unit, Novartis Institute for Biomedical Research
  • Linda King, Director, Oxford Expression Technologies Ltd
  • Ignacio Casal, Biotechnology Programme Director and Head of the Protein Technology Unit, Centro Nacional de Investigaciones Oncológicas (CNIO)
  • Balwant Patel, Director Market Development, Cloning and Protein Expression Buisness Unit, Invitrogen
  • Gisela Schnapp, Principal Scientist, Lead Discovery, Strutural Research Boehringer Ingelheim Pharma
  • Judit Nagy, Proteomics Facility Director, Institute of Biomedical Engineering, Imperial College London
  • Laurent Fourage, Project Leader, Biotechnology, Proteus
  • Nina Albrecht, Manager Scientific Sales, Geneart
  • Peter Hemmerich, Research Associate, FLI Leibniz Institute for Age Research
  • W. Antoni Kudlicki, Research Fellow, R&D, Invitrogen




You will benefit from attending this event if you are:

A Vice President, Director or Head of:

  • Gene expression
  • Biochemistry
  • Proteomics
  • Product Safety        
  • Clinical / Medical Affairs 
  • Protein expression
  • Protein purification
  • Scientific Affairs
  • Pharmacovigilance
  • Drug Surveillance
  • Regulatory Affairs
  • Pharmacokinetics



  • Last years’ delegates were from:

    • Pfizer
    • GlaxoSmithKline
    • Bayer-Schering Pharma            
    • Roche Products Ltd
    • Merck Research Labs
  • Wyeth Research
  • UCB-Celltech
  • AstraZeneca 
  • Roche Diagnostics GmbH                 
  • Boehringer Ingelheim Pharma
  • Actelion Pharmaceuticals Ltd
  • Labotatorios Almirall
  • Vertex Pharmaceuticals
  • Syngenta
  • Evotec OAI



  • For Speaking opportunities please contact Mamta Patel at mpatel@smi-online.co.uk
    For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk

    Conference programme

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Bernardo Perez-Ramirez

    Bernardo Perez-Ramirez, Scientific Director, BioFormulations Development, Genzyme Corporation

    9:10 GENE SYNTHESIS IN PROTEIN ENGINEERING

    Mark McAlister

    Mark McAlister, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca

  • The role of protein engineering
  • Conventional molecular biology vs. gene synthesis
  • Case studies
  • Future directions
  • 9:50 USE OF LABCHIP 90 IN PRODUCT DEVELOPMENT OF A RECOMBINANT FUSION PROTEIN

    Joseph Siemiatkoski

    Joseph Siemiatkoski, Senior Scientist, Biogen Idec

  • Method development timelines can be compressed using automation
  • Speed of analysis and high throughput are crucial for development efforts
  • Wide linear range simplifies operability and data analysis
  • For quantitation, selectivity of separation has benefits over traditional approaches
  • Data quality is improved by enabling replicate analysis – statistically justified purity data
  • 10:30 Morning Coffee

    11:00 STRUCTURE-FUNCTION STUDIES OF INTERLEUKIN-21

    Kent Bondensgaard

    Kent Bondensgaard, Research Scientist, Novo Nordisk

  • 3D structure of  IL-21
  • Conformational heterogeneity
  • Receptor interactions
  • Design of superpotent IL-21 analogues
  • Mechanisms for increased potency by cytokine analogues
  • 11:40 EXCELLENCE IN DNA ENGINEERING AND PROCESSING

    Nina Albrecht

    Nina Albrecht, Manager, Geneart AG

  • Expression optimisation – background, rationales and GENEART philosophy
  • The art of optimising genes: a multi-parameter challenge
  • Case studies of different expression systems pre and post optimisation
  • DNA engineering and processing workflow
  • Improved proteins by directed evolution
  • 12:20 PROTEIN CHARACTERISATION

    Indresh Srivastava

    Indresh Srivastava, Head of Protein Biology, Novartis Vaccines and Diagnostics

  • Select an appropriate expression systems
  • Strategies for selecting an appropriate structure for clinical evaluation
  • Production of selected vaccine
  • Purification of vaccine immunogen
  • Characterization of the vaccine using state of the art techniques for determining the conformation; glycosylation, epitope exposure, binding affinity, and stability
  • Clinical evaluation of vaccines
  • 13:00 Networking Lunch

    14:00 COMBINATORIAL DOMAIN HUNTING IN MOSAIC MODE

    Renos Savva

    Renos Savva, Senior Research Fellow, Birkbeck College, University of London

  • The provision of soluble, folded and stable recombinant protein
  • Combinatorial Domain Hunting (CDH) technology
  • Assessing time and resource effective approaches to expression construct design
  • Is it necessary to access bioinformatics analysis in construct making?
  • Provision of previously recombinantly intractable/ insoluble proteins
  • The isolation of protein-protein complexes in soluble, stable recombinant arrangements
  • Optimising recombinant expression for structure and drug design
  • 14:40 CASE STUDY: MULTI-PARALLEL PROTEIN PRODUCTION

    Ian Hunt

    Ian Hunt, Group Leader, Novartis

  • Utility of  multi-parallel E. coli baculovirus mediated protein expression strategies
  • Current bottlenecks within the process
  • Potential new and enabling technologies
  • 15:20 EXPRESSION TECHNOLOGIES

    Mark Abbott

    Mark Abbott, Principal Scientist, Respiratory and Inflammation, AstraZeneca

  • Multi-domain proteins
  • Methods to handle and analyse different post translational modifications
  • Mammalian expression with many different ‘flavours’
  • Easy access to mammalian, insect and E.coli expression systems essential for success
  • Different expression systems for different uses
  • Case studies of different protein families
  • 16:00 Afternoon Tea

    16:30 PROTEIN SEPARATION AND BIOMARKER DISCOVERY USING LABEL FREE INTRINSIC IMAGING

    Judit Nagy

    Judit Nagy, Proteomics Research Scientist, Imperial College London

  • Optimising the process
  • Methods used
  • Validation of marker candidates
  • Proteomic technologies  to find novel markers
  • 17:10 CELL-FREE EXPRESSION OF INTEGRAL MEMBRANE PROTEINS USING DISCOIDAL MEMBRANES

    W. Antoni Kudlicki

    W. Antoni Kudlicki, Research Fellow, R&D, Invitrogen

  • Discoidal membranes (NLPs)
  • NLP-based expression and solubilisation of membrane proteins
  • Cell-free production of medically relevant NLP-MP complexes using Expressway
  • Different strategies for complex formation
  • Functional analysis and ligand displacement assay for selected membrane protein targets
  • Characterisation of MP-NLP complexes
  • 17:50 Chairman’s Closing Remarks and Close of Day One

    Bernardo Perez-Ramirez

    Bernardo Perez-Ramirez, Scientific Director, BioFormulations Development, Genzyme Corporation

    18:00 Drinks Reception sponsored by Caliper LifeSciences

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Ian Hunt

    Ian Hunt, Group Leader, Novartis

    9:10 ASSESSING THE SOLUTION BEHAVIOR OF THERAPEUTIC PROTEINS

    Bernardo Perez-Ramirez

    Bernardo Perez-Ramirez, Scientific Director, BioFormulations Development, Genzyme Corporation

  • Biophysical approaches to pre-formulation
  • Maximizing data out put with minimal amounts of protein 
  • Global analysis and thermodynamic assessment
  • Choosing proper stress conditions
  • 9:50 PROTEIN EXPRESSION IN INSECT CELLS

    Linda King

    Linda King, Director, Oxford Expression Technologies Ltd

  • New vectors for multi-parallel protein production
  • Increasing yields and quality of difficult to express proteins
  • Rapid titration of baculovirus expression vectors
  • Micro scale and large scale protein production
  • 10:30 Morning Coffee

    11:00 A NOVARTIS CASE STUDY: KINASE AND PROTEASE PREPARATION

    Paul Ramage

    Paul Ramage, Senior Research Investigator 1, CPC/Protease Platform, Novartis Pharma AG

  • Overview/organisation
  • Problems faced
  • Solutions
  • Specific examples
  • Future directions
  • 11:40 ENGINEERING ENHANCED THERAPEUTIC PROTEINS

  • Protein engineering technologies
  • Examples
  • Optimisation of therapeutic proteins and antibodies
  • Basis of protein immunogenicity
  • Early assessment of protein immunogenicity
  • Immunogenicity engineering
  • Ingrid Marchal-Gerez

    Ingrid Marchal-Gerez, Business Development Manager, Proteus

    Laurent Fourage

    Laurent Fourage, Project Leader, Biotechnology, Proteus

    12:20 NOVEL TOOLS FOR HIGHER THROUGHPUT AND HIGHER PROTEIN YIELD IN MAMMALIAN AND INSECT CELLS

    Balwant Patel

    Balwant Patel, Director, Market Development, Cloning and Protein Expression Buisness Unit, Invitrogen

  • Multi-site Gateway® Pro, simultaneous cloning of up to four gene fragments into any Gateway® expression vector.
  • pFastBac™ TOPO and BaculoDirect™ systems for rapid high throughput insect expression
  • FreeStyle™ MAX System, a gram of protein from 293 or CHO cells in just one week
  • High efficiency gene delivery into almost impossible to transfect cell types with ViraPower HiPerformTM Lentivirus Expression System
  • 13:00 Networking Lunch

    14:00 LARGE SCALE PROTEIN PRODUCTION

    Florian Wurm

    Florian Wurm, Professor of Biotechnology, Ecole Polytechnique Federale De Lausanne

  • Multi-gram per litres - how to achieve this
  • DNA to process in the shortest time
  • Genetics and the biology of large scale manufacturing
  • Transient gene expression – the innovative new approach
  • Disposables at large scale?
  • 14:40 HIGH THROUGH PUT PROTEIN PURIFICATION

    Gisela  Schnapp

    Gisela Schnapp, Principal Scientist, Boehringer Ingelheim

  • Expression screening with small amount of protein
  • High through put protein purification methods for crystallisation trials
  • protein characterisation
  • Purity versus yield
  • Time and cost implications
  • Crystallisation methods
  • 15:20 PROTEOMICS-BASED VALIDATION OF GENOMIC DATA

    Ignacio Casal

    Ignacio Casal, Biotechnology Programme Director and Head of the Protein Technology Unit, CNIO

  • Parallel expression of multiple proteins
  • Evaluation of different approaches for antibody production
  • Phage display and PrEST technology
  • Validation strategies for tumoral biomarkers
  • 16:00 Afternoon Coffee

    16:30 STRUCTURE DETERMINATION OF PROTEIN-LIGAND COMPLEXES

    Rick Davies

    Rick Davies, Team Leader, AstraZeneca

  • Co-expression with ligands
  • Surface mutagenesis
  • Construct design
  • Hybridisation
  • Use of orthologues
  • 17:10 CHECKPOINT RESEARCH IN MITOSIS

    Peter Hemmerich

    Peter Hemmerich, Research Associate, FLI Leibniz Institute for Age Research

  • Effective cloning
  • In vivo fluorescence techniques (FRAP, FCS, FCCS, FRET, FLIM)
  • Structural architecture of the kinetochore
  • Dynamics of kinetochore proteins
  • Exemplary approach – its application to other cellular machineries
  • 17:50 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.